You are here

Proc Natl Acad Sci U S A DOI:10.1073/pnas.0803379105

Drug-sensitive FGFR2 mutations in endometrial carcinoma.

Publication TypeJournal Article
Year of Publication2008
AuthorsDutt, A, Salvesen, HB, Chen, T-H, Ramos, AH, Onofrio, RC, Hatton, C, Nicoletti, R, Winckler, W, Grewal, R, Hanna, M, Wyhs, N, Ziaugra, L, Richter, DJ, Trovik, J, Engelsen, IB, Stefansson, IM, Fennell, T, Cibulskis, K, Zody, MC, Akslen, LA, Gabriel, S, Wong, K-K, Sellers, WR, Meyerson, M, Greulich, H
JournalProc Natl Acad Sci U S A
Date Published2008 Jun 24
KeywordsAnimals, Carcinoma, Cell Line, Tumor, Cell Proliferation, Cell Survival, Endometrial Neoplasms, Female, Mice, Mutation, NIH 3T3 Cells, Receptor, Fibroblast Growth Factor, Type 2, Transfection

Oncogenic activation of tyrosine kinases is a common mechanism of carcinogenesis and, given the druggable nature of these enzymes, an attractive target for anticancer therapy. Here, we show that somatic mutations of the fibroblast growth factor receptor 2 (FGFR2) tyrosine kinase gene, FGFR2, are present in 12% of endometrial carcinomas, with additional instances found in lung squamous cell carcinoma and cervical carcinoma. These FGFR2 mutations, many of which are identical to mutations associated with congenital craniofacial developmental disorders, are constitutively activated and oncogenic when ectopically expressed in NIH 3T3 cells. Inhibition of FGFR2 kinase activity in endometrial carcinoma cell lines bearing such FGFR2 mutations inhibits transformation and survival, implicating FGFR2 as a novel therapeutic target in endometrial carcinoma.


Alternate JournalProc. Natl. Acad. Sci. U.S.A.
PubMed ID18552176
PubMed Central IDPMC2438391
Grant ListU24 CA126546 / CA / NCI NIH HHS / United States